Back to Search
Start Over
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
- Publication Year :
- 2021
-
Abstract
- Rat sarcoma (RAS) oncogenes have intensively been investigated during the last decades. Taking into account all human tumours, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene is the most frequently mutated (about 22%) among the three isoforms, followed by Neuroblastoma RAS Viral Oncogene Homolog (NRAS) (8%) and Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) (3%). In the last years, careful attention has been paid on KRAS and NRAS gene mutations in non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC) patients because of their prognostic and predictive roles. In particular, a large body of literature data has been generated investigating clinical outcomes of targeted treatments in NSCLC and CRC KRAS- and NRAS-mutated patients. The latest evidences are here reviewed, providing also an overview of the real-world RAS mutation testing practice across different Italian laboratories. On this basis, we propose a knowledge-based system, www.rasatlas.com, to support the healthcare personnel in the management of patients featuring RAS gene mutations in the landscape of precision oncology.
- Subjects :
- 0301 basic medicine
Neuroblastoma RAS viral oncogene homolog
Cancer Research
Lung Neoplasms
Colorectal cancer
Viral Oncogene
NRAS
Gene mutation
medicine.disease_cause
NSCLC
03 medical and health sciences
0302 clinical medicine
Neuroblastoma
Biomarkers, Tumor
KRAS
Medicine
CRC
NGS
Colorectal Neoplasms
Humans
ras Proteins
Mutation
HRAS
Lung cancer
neoplasms
Tumor
business.industry
medicine.disease
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Cancer research
business
Biomarkers
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....7d3b22e2752151b46b1284bbf5580088